Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. more
Time Frame | MLTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.39% | 0.31% | -1.26% |
1-Month Return | -12.23% | 0.6% | -4.16% |
3-Month Return | -4.91% | -9.44% | -0.46% |
6-Month Return | -4.91% | -5.15% | 3.58% |
1-Year Return | -19.35% | 0.33% | 22.47% |
3-Year Return | 370.17% | 4.53% | 25.13% |
5-Year Return | 343.28% | 35.98% | 77.7% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | 4.97K | 12.36K | 13.16K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":37.78,"profit":true},{"date":"2022-12-31","value":93.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | - | (4.97K) | (12.36K) | (13.16K) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-497100,"profit":false},{"date":"2022-12-31","value":-1235800,"profit":false},{"date":"2023-12-31","value":-1315800,"profit":false}] | |
Gross Margin | - | - | (Infinity%) | (Infinity%) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] | |
Operating Expenses | 105.75K | 4.57M | 65.06M | 54.12M | [{"date":"2020-12-31","value":0.16,"profit":true},{"date":"2021-12-31","value":7.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.19,"profit":true}] | |
Operating Income | (105.76K) | (4.57M) | (65.06M) | (54.12M) | [{"date":"2020-12-31","value":-10576000,"profit":false},{"date":"2021-12-31","value":-457034500,"profit":false},{"date":"2022-12-31","value":-6506141700,"profit":false},{"date":"2023-12-31","value":-5412309600,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (90.84K) | (4.54M) | (64.47M) | (43.98M) | [{"date":"2020-12-31","value":-9083800,"profit":false},{"date":"2021-12-31","value":-454265400,"profit":false},{"date":"2022-12-31","value":-6446968500,"profit":false},{"date":"2023-12-31","value":-4398472900,"profit":false}] | |
Income Taxes | (206.30K) | 5.71K | 36.37K | 94.39K | [{"date":"2020-12-31","value":-218.56,"profit":false},{"date":"2021-12-31","value":6.05,"profit":true},{"date":"2022-12-31","value":38.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | - | (4.54M) | (50.10M) | (52.66M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-454265400,"profit":false},{"date":"2022-12-31","value":-5009810700,"profit":false},{"date":"2023-12-31","value":-5265965700,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (90.84K) | (4.54M) | (64.51M) | (36.01M) | [{"date":"2020-12-31","value":-9083800,"profit":false},{"date":"2021-12-31","value":-454265400,"profit":false},{"date":"2022-12-31","value":-6450605100,"profit":false},{"date":"2023-12-31","value":-3600726000,"profit":false}] | |
EPS (Diluted) | (0.01) | (0.31) | (1.27) | (0.76) | [{"date":"2020-12-31","value":-1,"profit":false},{"date":"2021-12-31","value":-31,"profit":false},{"date":"2022-12-31","value":-127,"profit":false},{"date":"2023-12-31","value":-76,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
MLTX | |
---|---|
Cash Ratio | 24.60 |
Current Ratio | 25.51 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MLTX | |
---|---|
ROA (LTM) | -13.32% |
ROE (LTM) | -16.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MLTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.94 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MLTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 6.01 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
MoonLake Immunotherapeutics (MLTX) share price today is $46.5
Yes, Indians can buy shares of MoonLake Immunotherapeutics (MLTX) on Vested. To buy MoonLake Immunotherapeutics from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MLTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of MoonLake Immunotherapeutics (MLTX) via the Vested app. You can start investing in MoonLake Immunotherapeutics (MLTX) with a minimum investment of $1.
You can invest in shares of MoonLake Immunotherapeutics (MLTX) via Vested in three simple steps:
The 52-week high price of MoonLake Immunotherapeutics (MLTX) is $64.98. The 52-week low price of MoonLake Immunotherapeutics (MLTX) is $37.55.
The price-to-earnings (P/E) ratio of MoonLake Immunotherapeutics (MLTX) is
The price-to-book (P/B) ratio of MoonLake Immunotherapeutics (MLTX) is 6.01
The dividend yield of MoonLake Immunotherapeutics (MLTX) is 0.00%
The market capitalization of MoonLake Immunotherapeutics (MLTX) is $2.93B
The stock symbol (or ticker) of MoonLake Immunotherapeutics is MLTX